Clinical Trials Logo

Soft Tissue Sarcoma Adult clinical trials

View clinical trials related to Soft Tissue Sarcoma Adult.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04577014 Active, not recruiting - Sarcoma Clinical Trials

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Start date: September 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to find out whether the study drug Retifanlimab, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that are commonly used to treat soft tissue sarcoma. Retifanlimab is an experimental drug that boosts the immune system's ability to fight cancer cells. The study researchers think that Retifanlimab may help gemcitabine and docetaxel work better against soft tissue sarcoma that is either locally advanced or has spread beyond its original location (metastasized), and it cannot be removed with surgery (unresectable).

NCT ID: NCT03526679 Active, not recruiting - Advanced Cancer Clinical Trials

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

LEADER
Start date: July 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma.